Physician profile
Daniel Renois
NPI 1316043730
$3,391.81
in general payments reported to CMS, 2019-2025
35 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $661 · 2021: $274 · 2022: $417 · 2023: $328 · 2024: $371 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.26 | 2020-2025 | |
| Novo Nordisk INC | $526.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $286.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $277.84 | 2019-2023 | |
| Lilly USA, LLC | $165.14 | 2019-2023 | Trulicity |
| Otsuka America Pharmaceutical, INC. | $161.22 | 2019-2025 | Rexulti, Nuedexta |
| Melinta Therapeutics, LLC | $128.49 | 2019-2023 | Rezzayo, Orbactiv, Kimyrsa |
| Amgen INC. | $101.45 | 2019-2025 | Otezla, Repatha, Evenity |
| Organogenesis INC. | $100.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.55 | 2019-2020 | |
| Abbott Laboratories | $74.29 | 2021-2024 | Freestyle Libre 3 |
| Fresenius USA Marketing, INC. | $71.94 | 2019-2020 | |
| Axsome Therapeutics, INC. | $71.21 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $69.69 | 2019-2020 | |
| Dexcom, INC. | $66.74 | 2022-2023 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.22 | 2020-2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.70 | 2020-2023 | Jardiance |
| Amarin Pharma, INC. | $41.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $40.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $32.13 | 2020-2023 | Shingrix, Trelegy Ellipta |
| Acadia Pharmaceuticals INC | $32.06 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $29.23 | 2020-2022 | |
| Allergan, INC. | $28.75 | 2019-2020 | |
| Smith+Nephew, INC. | $24.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.44 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $19.76 | 2019 | |
| Kyowa Kirin, INC. | $19.30 | 2024 | Crysvita |
| Sumitomo Pharma America, INC. | $18.66 | 2024 | Gemtesa |
| Ardelyx, INC. | $18.46 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2020 | |
| Exact Sciences Corporation | $14.56 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $13.98 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $13.61 | 2025 | |
| Eisai INC. | $13.24 | 2020 | |
| Vifor Pharma, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Renois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.